Marvel Biosciences (TSXV:MRVL) LT-Debt-to-Total-Asset : 7.47 (As of Oct. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Marvel Biosciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Marvel Biosciences's long-term debt to total assests ratio for the quarter that ended in Oct. 2024 was 7.47.

Marvel Biosciences's long-term debt to total assets ratio increased from Oct. 2023 (2.30) to Oct. 2024 (7.47). It may suggest that Marvel Biosciences is progressively becoming more dependent on debt to grow their business.

Marvel Biosciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Marvel Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences LT-Debt-to-Total-Asset Chart

Marvel Biosciences Annual Data

Trend

Jul20

Jul21

Jul22

Jul23

Jul24

LT-Debt-to-Total-Asset

1.49

3.48

Marvel Biosciences Quarterly Data
	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial													2.30	2.11	4.32	3.48	7.47

Marvel Biosciences LT-Debt-to-Total-Asset Calculation

Marvel Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jul. 2024 is calculated as

LT Debt to Total Assets (A: Jul. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Jul. 2024 )	/	Total Assets (A: Jul. 2024 )
	=	1.71	/	0.491
	=

Marvel Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Oct. 2024 is calculated as

LT Debt to Total Assets (Q: Oct. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Oct. 2024 )	/	Total Assets (Q: Oct. 2024 )
	=	1.71	/	0.229
	=

Marvel Biosciences (TSXV:MRVL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Marvel Biosciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (TSXV:MRVL) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

MBCOF:USA

Address

505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2

Website

https://www.marvelbiotechnology.com

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Executives